title: Socioeconomic position and secondary preventive therapy after an AMI.
abstract: OBJECTIVE
  To investigate the association between socioeconomic position and use of lipid-lowering drugs and ACE-inhibitors after an acute myocardial infarction (AMI) when simultaneously considering participation in the national quality register RIKS-HIA (Register of Information and Knowledge about Swedish Heart Intensive care Admissions), age, sex and previous hospitalizations of the patients.
  
  
  METHODS
  Population-based prospective cohort study included all 1346 AMI patients cared in the county of Scania, Sweden during 2006 of whom 1061 were register at the RIKS-HIA. Treatment with lipid-lowering and ACE-inhibiting therapy in relation to income was investigated with Cox and logistic regression modelling.
  
  
  RESULTS
  In the whole population of AMI patients, high income patients had a higher adherence to guidelines for pharmacological secondary prevention than low income patients (HR(lipid-lowering drug): 1.29; 95%CI: 1.12-1.49 and HR(ACE-inhibitor therapy): 1.22; 95%CI: 1.04-1.43). Among RIKS-HIA participants, patients with high income presented a better adherence to lipid-lowering treatment than patients with low income (HR: 1.15; 95%CI: 0.98-1.34).
  
  
  CONCLUSIONS
  Our investigation reveals that the Swedish goal of access to health care on equal terms and according to needs is still not fully accomplished. Moreover, since this pattern of inequity in pharmacological secondary prevention may lead to the recurrence of heart disease, these inequities are not only a matter of fairness and social justice, but also a potential (and modifiable) source of ineffectiveness and inefficiency in health care.
authors.affiliation: Faculty of Medicine, Social Epidemiology, Lund University, Malmö, Sweden. henrik.ohlsson@med.lu.se
authors.forename: Henrik
authors.initials: H
authors.lastname: Ohlsson
authors.forename: Maria
authors.initials: M
authors.lastname: Rosvall
authors.forename: Ole
authors.initials: O
authors.lastname: Hansen
authors.forename: Basile
authors.initials: B
authors.lastname: Chaix
authors.forename: Juan
authors.initials: J
authors.lastname: Merlo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D010349:Patient Compliance / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012042:Registries; D055502:Secondary Prevention; D012959:Socioeconomic Factors; D013548:Sweden / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000960:Hypolipidemic Agents